Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops aim to halt keratoconus progression

NCT ID NCT07400952

Disease control Sponsor: Glaukos Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether GLK-221 eye drops can safely slow the progression of keratoconus, a condition that thins and bulges the cornea. About 100 adults with keratoconus will use the drops twice daily for several months. The main goal is to see if the drops reduce the steepening of the cornea compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLK-221 ophthalmic solution (eye drops)
What this could lead to
If successful, this could provide a non-surgical treatment to slow or stop the progression of keratoconus, potentially reducing the need for corneal transplants.
What could go wrong
This is an early Phase 2 trial with only 100 participants, so results may not confirm effectiveness. The treatment may not slow the disease or could cause side effects like eye irritation.
Why investors are watching

Glaukos is testing GLK-221, an eye drop for keratoconus, a disease that thins and bulges the cornea. This Phase 2 trial compares the drug against a placebo in 100 patients, and a positive result would give the small company a new product line beyond its existing surgical devices. For a company of this size, this readout could shape its pipeline and future growth.

If it works: If the trial shows GLK-221 safely slows or stops keratoconus progression, Glaukos could move the drug into later-stage testing and eventually offer a non-surgical treatment option. That success would broaden the company's portfolio and reduce its reliance on its current products.

If it fails: Phase 2 trials often fail to show a clear benefit over placebo, and a negative or unclear result would likely end GLK-221's development. That outcome would leave Glaukos without this potential new drug and could delay its pipeline plans.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be ≥ 18 and ≤ 55 years of age * Diagnosis of keratoconus in the study eye Exclusion Criteria: * Pregnant, lactating or planning a pregnancy * Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Keratoconus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

keratoconus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Keratoconus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Glaukos Clinical Study Site

    RECRUITING

    Westerville, Ohio, 43082, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.